Compare Caesars Entertainment Inc (CZR) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Davita Inc — how do they compare? Caesars Entertainment Inc trades at $29.54 (market cap $6.02B), while Davita Inc trades at $178.24 (market cap $11.29B). The key difference: Davita Inc is the larger of the two by market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Davita Inc for 113 Days on average.
| CZR | DVA | |
|---|---|---|
Market Cap | $6.02B | $11.29B |
Volume | 6,412,151 | 582,204 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $240.96 |
52-Week Low | $18.14 | $103.87 |
Typical Hold Time | 31 Days | 113 Days |
Enterprise Value | $29.91B | $24.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.49, down 0.54% on the day, with a bearish technical signal and recent earnings misses. The company reported a net loss of -$502 million for 2025, with negative profit margins and ROE, though operating cash flow remains strong at $1.3 billion. A pending merger with Fertitta Entertainment for $31.00 per share is under regulatory review, with several law firms investigating the deal's fairness.
CZR presents a cautious outlook with merger uncertainty and persistent losses offset by stable revenue and cash generation. The consensus price target of $30.75 offers modest upside, but investors face risks from debt levels, regulatory scrutiny, and competitive pressures in the gaming sector.
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
